CX3CR1 and Mental deterioration: Inhibition of oxidative stress mediated by Aβ1-42 oligomers and the rescue of the fractalkine receptor CX3CR1 have been recently considered as novel therapeutic strategies to prevent neuronal loss and cognitive decline in AD pathology.